Analyst firms · Morgan Stanley · BLUE

Morgan Stanley BLUE price target and rating history

bluebird bio Inc. (BLUE) · Health Care

Morgan Stanley rates bluebird bio Inc. (BLUE) Equal-Weight with a $7 price target, as of its latest action on Dec 8, 2023. It has published 5 rating actions on BLUE since July 2021, including 1 upgrade and 1 downgrade.

Current rating
Equal-Weight
Price target
$7
Median target, all firms
Too few
Actions on BLUE
5

Morgan Stanley price target on BLUE

$35$20$520222023202420252026
Morgan Stanley price target on BLUE, each point a stated target, July 2021 to December 2023.

Every Morgan Stanley rating on BLUE

Questions about Morgan Stanley and BLUE

What is Morgan Stanley's price target for BLUE?
Morgan Stanley's latest stated price target for bluebird bio Inc. (BLUE) is $7, from its action on Dec 8, 2023.
What is Morgan Stanley's rating on BLUE?
Morgan Stanley rates BLUE Equal-Weight, a neutral rating, as of Dec 8, 2023.
When did Morgan Stanley last change its view on BLUE?
On Dec 8, 2023, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $3 to $7.

More BLUE rating histories

All Morgan Stanley ratingsBLUE news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.